Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Feasibility Testing of Plant-Based Supplemented Food Products Made With Manitoba Crop Ingredients for Weight Loss

15 septembre 2026 mis à jour par: Dylan MacKay, University of Manitoba

The purpose of this study is to advance the development of the WI/CDIC supplemented foods by evaluating the acceptance and feasibility of the supplemented food bars within the Wellness Institute's Weight Loss Clinic program (WLC) or an equivalent weight loss program in Winnipeg or the surrounding area. The main questions it aims to answer are:

  • To determine whether the incorporation of WI/CDIC supplemented foods into the WI weight loss clinic design is feasible.
  • To determine whether weight loss is supported by a plant-based supplemented food.
  • To assess efficacy of the supplemented food by measuring changes in lifestyle behaviours and risk factors for chronic disease compared to non-supplemented food weight loss program members.

Researchers will compare the WLC program plus supplemented food to the WLC program without the supplemented food to evaluate the implementation of the supplemented foods into the WLC.

Participants will follow their WLC program for the initial 16 weeks, and those in the intervention group will begin their supplemented food. Participants will consume one supplemented food bar each day and will record this in the product consumption log.

Aperçu de l'étude

Statut

Pas encore de recrutement

Les conditions

Description détaillée

This is a pilot evaluation of the feasibility of incorporating the WI/CDIC supplemented food into the WI's newly designed WLC. This study will employ a mixed methods quasi-experimental approach using questionnaires and data collected over the evaluation period. Following consent, participants will be asked to fill out a set of questionnaires, to capture dietary intake, and to wear an activity monitor; to measure diet, physical activity, QOL and sleep before each study meeting. Eligible participants (n=40) will be randomized to intervention (supplemented food) or no intervention. Participants will attend two in-person study visits - one at the initiation and one at the completion of the 16-week weight loss program. Body weight, height, waist circumference, blood pressure and heart rate will be recorded at these two time points as well, as collected through the weight loss clinic program. Participants will also complete an exit questionnaire at the second visit that will include a 9-point hedonic scale to evaluate product acceptability.

Type d'étude

Interventionnel

Inscription (Estimé)

40

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

    • Manitoba
      • Winnipeg, Manitoba, Canada, R2V 3M3
        • Seven Oaks Hospital Chronic Disease Innovation Centre
        • Contact:
        • Sous-enquêteur:
          • Dr Rebecca Mollard, PhD

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Male or female, aged 18 years or above
  • Live within the province of MB
  • Ability to give written informed consent in English.
  • Enrolled in the Wellness Institute Weight Loss Clinic or an equivalent, approved weight loss program in Winnipeg or the surrounding area.

Exclusion Criteria:

  • Female participant who is pregnant, lactating or planning pregnancy during the course of the program.
  • Participants with known allergies to the supplemented food ingredients
  • Has an active eating disorder

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur actif: The WLC program plus supplemented food

Participants in weight loss clinic program will consume one supplemented food bar each day and will record this in the product consumption log.

These supplemented foods provide plant-based protein, fibre and fatty acids that have been shown to have health benefits related to chronic disease.

Aucune intervention: The WLC program only

Participants in the weight loss clinic only.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Feasibility of incorporating the WI/CDIC supplemented foods into the WI weight loss clinic.
Délai: End of Study (Week 16)

Feasibility will be demonstrated if the following five criteria are met:

  1. Eligibility to randomization ratio is greater than 0.5, calculated as the ratio of individuals within the WI WLC program who were randomized to the trial to the number eligible to participate who were approached to participate.
  2. The percentage of participants who complete the 16-week program in the supplemented food arm is equivalent (plus or minus 10%) or greater than the standard arm.
  3. Follow up of greater than 85% of participant outcomes.
  4. Adherence to the supplemented food intervention calculated by consumption of >75% dispensed products as documented in the Product Consumption Log
  5. Product Acceptability using an Exit Questionnaire consisting of a 9-point hedonic box scale to assess mean acceptability values of 6 or greater (like at least slightly) in 75% or more of the participants.
End of Study (Week 16)

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Changes in Body Weight
Délai: At Enrollment (Week 0) and End of Study (Week 16)

Body weight will be measured in kg to the nearest 0.1 kg by an exercise professional.

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Waist Circumference
Délai: At Enrollment (Week 0) and End of Study (Week 16)

Waist circumference in cm will be measured to the nearest 0.1 cm at the umbilicus, between the last rib and iliac crest using a fibreglass tape measured by an exercise professional.

At Enrollment (Week 0) and End of Study (Week 16)
Changes in BMI
Délai: At Enrollment (Week 0) and End of Study (Week 16)

Body Mass Index will be calculated using the formula BMI = kg/m2; where kg is the weight in kilograms and m2 is height in metres squared.

At Enrollment (Week 0) and End of Study (Week 16)
Cardiovascular Assessment
Délai: At Enrollment (Week 0) and End of Study (Week 16)

Using the Framingham Risk Score, cardiovascular risk will be calculated based on age, HDL-C, total cholesterol, systolic blood pressure, smoking status, and diabetes status to determine the participant's 10-year risk of cardiovascular disease and identification of metabolic syndrome.

At Enrollment (Week 0) and End of Study (Week 16)
Changes is Quality of Life
Délai: At Enrollment (Week 0) and End of Study (Week 16)

Quality of life will be measured through the SF-36 quality of life questionnaire. The SF-36 measures nine areas: physical functioning, role functioning (emotional), role functioning (physical), energy/fatigue, emotional well-being, social functioning, pain, general health, and health change. A higher score indicates greater levels of quality of life.

At Enrollment (Week 0) and End of Study (Week 16)

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Changes in Systolic Blood Pressure
Délai: At Enrollment (Week 0) and End of Study (Week 16)

Systolic blood pressure in mmHg is measured in triplicate, on the non-dominant arm in a sitting position by an exercise professional using a validated oscillometric blood pressure monitor.

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Diastolic Blood Pressure
Délai: At Enrollment (Week 0) and End of Study (Week 16)

Diastolic blood pressure in mmHg is measured in triplicate, on the non-dominant arm in a sitting position by an exercise professional using a validated oscillometric blood pressure monitor.

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Heart Rate
Délai: At Enrollment (Week 0) and End of Study (Week 16)

Heart rate in beats per minute is measured in triplicate, on the non-dominant arm in a sitting position by an exercise professional using a validated oscillometric blood pressure monitor.

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Physical Activity
Délai: At Enrollment (Week 0) and End of Study (Week 16)

Measured using the International Physical Activity Questionnaire - Short Form - (IPAQ-S)

At Enrollment (Week 0) and End of Study (Week 16)
Change in Physical Activity Behaviour Patterns
Délai: At Enrollment (Week 0) and End of Study (Week 16)

Assessed using total active minutes per day as measured by multi-directional accelerometry for 7 days. Participants will be asked to wear the accelerometer at all times.

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Dietary Intake Behaviours
Délai: At Enrollment (Week 0) and End of Study (Week 16)

Dietary intake behaviours will be measured through The Mindful Eating Questionnaire. The Mindful Eating Questionnaire recognizing patterns of overeating or eating in response to stress, boredom, or other emotions. Scoring is based on five categories, which include Awareness (being aware of how food looks, tastes and smells); Distraction (focusing on other things while eating); Disinhibition (eating even when full); Emotional Response (eating in response to sadness or stress); and External Cues (eating in response to environmental cues, such as advertising)

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Dietary Intake Behaviours
Délai: At Enrollment (Week 0) and End of Study (Week 16)

Changes in dietary intake behaviours will be measured through the Three Factor Eating Questionnaire which is comprised of 18 items, measuring uncontrolled eating, restrained eating and emotional eating. The higher the score represents more dependency to cognition, stress or emotion the eating patterns.

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Dietary Intake - Number of Meals
Délai: At Enrollment (Week 0) and End of Study (Week 16)

Number of meals will be captured with a meal being defined as food intake greater than 500 kcal. Dietary intake will be captured using the RxFood app. RxFood is a type of AI-driven, image based dietary assessment tool that has already demonstrated clinical benefits in various adult and pediatric clinical settings and in research as a data collection tool. Strong correlation and strength of agreement have been illustrated between RxFood and nutrient estimates from Esha's Research Nutrition analysis software, which is an industry choice for nutritional analysis and regulatory compliance (Jefferson et al, 2020).

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Dietary Intake - Number of Snacks
Délai: At Enrollment (Week 0) and End of Study (Week 16)

Number of snacks will be captured with a meal being defined as food intake less than 500 kcal. Dietary intake will be captured using the RxFood app. RxFood is a type of AI-driven, image based dietary assessment tool that has already demonstrated clinical benefits in various adult and pediatric clinical settings and in research as a data collection tool. Strong correlation and strength of agreement have been illustrated between RxFood and nutrient estimates from Esha's Research Nutrition analysis software, which is an industry choice for nutritional analysis and regulatory compliance (Jefferson et al, 2020).

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Dietary Intake - Energy
Délai: At Enrollment (Week 0) and End of Study (Week 16)

Energy will be measured in kCals and will be captured using the RxFood app. RxFood is a type of AI-driven, image based dietary assessment tool that has already demonstrated clinical benefits in various adult and pediatric clinical settings and in research as a data collection tool. Strong correlation and strength of agreement have been illustrated between RxFood and nutrient estimates from Esha's Research Nutrition analysis software, which is an industry choice for nutritional analysis and regulatory compliance (Jefferson et al, 2020).

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Dietary Intake - Protein
Délai: At Enrollment (Week 0) and End of Study (Week 16)

Protein will be measured in grams and will be captured using the RxFood app. RxFood is a type of AI-driven, image based dietary assessment tool that has already demonstrated clinical benefits in various adult and pediatric clinical settings and in research as a data collection tool. Strong correlation and strength of agreement have been illustrated between RxFood and nutrient estimates from Esha's Research Nutrition analysis software, which is an industry choice for nutritional analysis and regulatory compliance (Jefferson et al, 2020).

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Dietary Intake - Fat
Délai: At Enrollment (Week 0) and End of Study (Week 16)

Fat will be measured in grams and will be captured using the RxFood app. RxFood is a type of AI-driven, image based dietary assessment tool that has already demonstrated clinical benefits in various adult and pediatric clinical settings and in research as a data collection tool. Strong correlation and strength of agreement have been illustrated between RxFood and nutrient estimates from Esha's Research Nutrition analysis software, which is an industry choice for nutritional analysis and regulatory compliance (Jefferson et al, 2020).

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Dietary Intake - Available Carbohydrates
Délai: At Enrollment (Week 0) and End of Study (Week 16)

Available carbohydrates will be measured in grams and will be captured using the RxFood app. RxFood is a type of AI-driven, image based dietary assessment tool that has already demonstrated clinical benefits in various adult and pediatric clinical settings and in research as a data collection tool. Strong correlation and strength of agreement have been illustrated between RxFood and nutrient estimates from Esha's Research Nutrition analysis software, which is an industry choice for nutritional analysis and regulatory compliance (Jefferson et al, 2020).

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Dietary Intake - Fibre
Délai: At Enrollment (Week 0) and End of Study (Week 16)

Fibre will be measured in grams and will be captured using the RxFood app. RxFood is a type of AI-driven, image based dietary assessment tool that has already demonstrated clinical benefits in various adult and pediatric clinical settings and in research as a data collection tool. Strong correlation and strength of agreement have been illustrated between RxFood and nutrient estimates from Esha's Research Nutrition analysis software, which is an industry choice for nutritional analysis and regulatory compliance (Jefferson et al, 2020).

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Sleep Patterns
Délai: At Enrollment (Week 0) and End of Study (Week 16)

An ActiGraph activity monitor will be used to measure sleep quality patterns for 7 days, with participants asked to wear the monitor at all times, including when they sleep.

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Total Cholesterol
Délai: At Enrollment (Week 0) and End of Study (Week 16)

Diagnostic Services of Manitoba will collect and process the participants blood samples and measure the total cholesterol concentration in mmol/L according to their established protocols.

At Enrollment (Week 0) and End of Study (Week 16)
Changes in High density lipoprotein cholesterol
Délai: At Enrollment (Week 0) and End of Study (Week 16)

Diagnostic Services of Manitoba will collect and process the participants blood samples and measure the total cholesterol concentration in mmol/L according to their established protocols.

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Low density lipoprotein cholesterol
Délai: At Enrollment (Week 0) and End of Study (Week 16)

Diagnostic Services of Manitoba will collect and process the participants blood samples and measure the total cholesterol concentration in mmol/L according to their established protocols.

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Triglycerides
Délai: At Enrollment (Week 0) and End of Study (Week 16)

Diagnostic Services of Manitoba will collect and process the participants blood samples and measure the total cholesterol concentration in mmol/L according to their established protocols.

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Total Cholesterol and High-Density Lipoprotein Cholesterol Ratio
Délai: At Enrollment (Week 0) and End of Study (Week 16)

Diagnostic Services of Manitoba will collect and process the participants blood samples and measure the total cholesterol concentration in mmol/L according to their established protocols.

At Enrollment (Week 0) and End of Study (Week 16)
Changes in Hemoglobin A1C
Délai: At Enrollment (Week 0) and End of Study (Week 16)

Diagnostic Services of Manitoba will collect and process the participants blood samples and measure the total cholesterol concentration in mmol/L according to their established protocols.

At Enrollment (Week 0) and End of Study (Week 16)

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Dr Dylan MacKay, PhD, University of Manitoba

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 novembre 2026

Achèvement primaire (Estimé)

31 décembre 2027

Achèvement de l'étude (Estimé)

31 décembre 2027

Dates d'inscription aux études

Première soumission

23 septembre 2024

Première soumission répondant aux critères de contrôle qualité

23 septembre 2024

Première publication (Réel)

26 septembre 2024

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

21 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

15 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

De-identified individual participant data (IPD) may be placed in a repository if required by a journal for publication purposes. De-identified IPD may also be requested from the principle investigator.

Délai de partage IPD

Data will become available following the publication of the primary results manuscript.

Critères d'accès au partage IPD

Researchers who provide a methodologically sound proposal and whose proposed use of the data has been approved by the trial PI.

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE
  • SÈVE
  • CIF
  • ANALYTIC_CODE
  • RSE

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner